Undisclosed RNF31 inhibitor / Flindr Therap - LARVOL DELTA

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors (PRNewswire) - "Flindr Therapeutics B.V...announces a €20 million Series A financing to advance its pipeline of first-in-class, small molecule inhibitors for treatment of cancer. V-Bio Ventures led the financing alongside other new investors Johnson & Johnson Innovation – JJDC, Inc. (JJDC), QBIC Fund, Flanders Future Tech Fund and Curie Capital, as well as existing investors Oncode Oncology Bridge Fund, Swanbridge and Brabantse Ontwikkelings Maatschappij (BOM)....Flindr's lead program is a first-in-class small molecule inhibitor of RNF31 (also known as HOIP), a protein-stabilizing E3 ubiquitin ligase which is aberrantly activated in solid and hematological malignancies....Flindr will use the funds to progress its lead program to IND, develop an exciting second program, and broaden its pipeline using the ImmunoGram Drug Discovery Engine."

Financing • Hematological Malignancies • Oncology • Solid Tumor